Introduction to synthetic peptide of larazotide

Larazotide (synthetic peptide) is an inhibitor polypeptide, which is composed of 8 amino acids. It is also the main raw material of the third phase clinical treatment drug for celiac disease. In vivo, larazotide (synthetic peptide) can promote the normal tight junction of intestinal cells in patients with chylosis, and prevent the glycolysis product of Glutenin from entering the systemic circulation, causing inflammatory reaction. All products of nutribio are for scientific research only. We do not provide products and services for any personal use.

The molecular weight of larazotide was 725.83

biological activity

in vitro

Larazotide inhibited the redistribution and rearrangement of band atresia-1 and muscle proteins induced by AT-1002 and maltol soluble protein fragments in Caco-2 and IEC6 cells. Larazotide inhibited the decrease of Teer and the opening of TJ in Caco-2 cells induced by AT-1002. Larazotide inhibited the transport of gliadin 13 mer peptide, which was related to chyloperitoneum and crossed the Caco-2 cell monolayer. In addition, top application of larazotide could inhibit the increase of TJ permeability induced by basal lateral application of cytokines.

in vivo

In vivo, larazotide inhibited the accumulation of megaphagocytes in the intestine induced by gliadin and maintained the normal tight junction structure in vivo in hla-hcd4 / DQ8 double transgenic mice.

Experimental reference method

Cell analysis

Caco-2 cells were seeded on a 12 well plate and grew for 21-28 days until fully differentiated. The top and basal lateral compartments of Caco-2 cell monolayer were pre incubated in Hank and s balanced salt solution (HbSS) at 37 ℃ for 30 minutes. 7.5mmly with or without AT-1002 (7mm) and different concentrations of lanotide acetate (5,10,12.5,15mm) in HbSS were added into the top compartment of each monolayer, and incubated at 37 ℃ for 50 rpm for 180 minutes. At the end of incubation, the samples were taken from the outer chamber of the base and analyzed in a fluorescent plate reader at 485 nm and 535 nm respectively. The ly channel increase of each treatment was calculated, and the performance of untreated was compared

The accuracy of these methods has not been independently confirmed by nutribio. For reference only.

Animal Administration

mouse

Hla-hcd4 / DQ8 mice (n = 10 in each group) were sensitized with 500 μ g of gliadin in 50 μ g complete Freund's adjuvant (IP) in 0.02 mm acetic acid, and then were treated with maltol soluble protein (2mg / mouse), + / - for 7 weeks. The first group received prazosin acetate (250 μ g / mouse), the second group and the second group received AT-1002 (250 μ g / mouse) and Millin, and the third group only received Millin. A group of non sensitive controls (CFA, only IP) were fed with rice. After 24 hours of gavage, the intestinal tissues were installed in the Ussing chamber to measure electrical parameters (ISC, conductivity) and macromolecular transport (horseradish peroxidase [HRP] flux). The number of megaphagocytes in tissues was treated by immunohistochemistry using F4 / 80 antibody specific to the glycoprotein of megaphagocyte limiting cells.

The accuracy of these methods has not been independently confirmed by nutribio. For reference only.

If the original article is reprinted, please indicate the source（ www.gotopbio.com ）”